Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiangdi Meng has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Delta-Radiomics Identifies Treatment-Fraction-Associated Features Linked to Outcomes After Carbon-Ion Radiotherapy for Head and Neck Cancer

    by Xiangdi Meng, Zhuojun Ju, Nobuteru Kubo, Atsushi Musha, Tatsuya Ohno

    Background: Longitudinal imaging during carbon-ion radiotherapy (CIRT) may capture dose-related tumor evolution before clinical assessment. We investigated whether serial CT-based Δ-radiomic features follow treatment-fraction (dose escalation)-associated trajectories with prognostic relevance in patients with head and neck cancer (HNC) treated with CIRT. Methods: We analyzed 167 HNC patients receiving 16-fraction CIRT. Features were extracted from plan-CT, confirm-CT, and weekly-CT scans after 5, 9, and 13 fractions. Δ-radiomic features were defined as time-normalized relative changes from confirm-CT. Linear mixed-effects models, paired Wilcoxon signed-rank tests, and monotonicity assessments identified features with systematic longitudinal changes. Endpoints were progression-free survival (PFS), overall survival (OS), and local recurrence (LR). Optimal prediction timing was determined using optimism-corrected C-indices. Bootstrap resampling and multivariable Cox models assessed cutoff stability and incremental value beyond clinical factors. Results: During a median follow-up of 15.2 months (range: 1.2–67.7), 64 PFS events, 18 deaths, and 24 local recurrences occurred. Five, eight, and six candidate Δ-radiomic features were retained for PFS, OS, and LR. Selected prediction time points spanned fractions 5, 9, and 13. In multivariable analyses, four PFS-related features met the predefined robustness criteria and improved discrimination over the clinical model (C-index, 0.646–0.661 vs. 0.580; likelihood ratio test, p = 0.002–0.004). Sequential adjustment retained two OS-related and two LR-related features. Exploratory histology-specific analyses provided some support, primarily for two PFS-related features. Conclusions: Serial CT-based delta-radiomics identified treatment-fraction-associated imaging features associated with clinical endpoint risk after CIRT for HNC, particularly PFS. These findings are exploratory and require prospective external validation before clinical application.

  • Open Access

    A delta-based multi-omics model to predict adaptive radiotherapy benefit in patients with non-small cell lung cancer during carbon-ion radiotherapy

    by Zhuojun Ju, Nobuteru Kubo, Xiangdi Meng, Makoto Sakai, Mutsumi Tashiro, Tatsuya Ohno

    Objective. Patients with non-small cell lung cancer (NSCLC) treated with carbon-ion radiotherapy (CIRT) are potential candidates for adaptive radiotherapy (ART). However, ART is time- and resource-intensive. This study aimed to develop a decision-support tool to estimate ART demand before treatment. Approach. This retrospective study included 69 patients with NSCLC treated with CIRT. Baseline clinical characteristics, dose–volume histogram (DVH) parameters, and radiomic and dosiomic features from the plan-computed tomography (CT) (1–2 weeks before treatment) and confirm-CT (1–2 days before treatment) were collected, and relative change rates in features (ΔDVH, Δradiomics, and Δdosiomics) were calculated. Feature selection involved univariable testing, correlation analysis, least absolute shrinkage and selection operator regression, and stepwise regression with 1000 bootstrap resamples. A multivariable logistic regression model was constructed and validated using 200 iterations of five-fold cross-validation. Main Results. ART was triggered in 32 (46.4%) patients. A five-feature delta-omic model (one ΔDVH, two Δradiomic, and two Δdosiomic features) achieved a validated median area under the curve of 0.897 (interquartile range, 0.833–0.950) with good calibration. At a high-sensitivity threshold (0.11), the model identified all ART candidates while potentially reducing the frequency of weekly-CT evaluations in 21.4% of patients; at the maximum-Youden threshold (0.41), the median accuracy reached 78.6%, with up to 50.0% classified as low ART demand. Significance. A delta-omic model predicting ART demand in patients with NSCLC receiving CIRT was developed. The model may help optimize resource allocation and streamline ART workflows, although prospective validation in larger cohorts is warranted before widespread clinical adoption.

  • Open Access

    Cumulative Dose Analysis in Adaptive Carbon Ion Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

    by Zhuojun Ju, Makoto Sakai, Xiangdi Meng, Nobuteru Kubo, Hidemasa Kawamura, Tatsuya Ohno

    Objectives: This study aimed to assess the precision of dose delivery to the target in adaptive carbon ion radiotherapy (CIRT) for locally advanced non-small cell lung cancer (LA-NSCLC) in cumulative dosimetry. Methods: Forty-six patients who received CIRT were included (64 Gy[relative biological effectiveness, RBE] in 16 fractions) with treatment plan computed tomography (CT) and weekly CT scans. Offline adaptive radiotherapy (ART) was administered if the dose distribution significantly worsened. Daily doses were calculated from weekly CTs and integrated into plan CT scans using deformable image registration. The dosimetry parameters were compared between the as-scheduled plan and adaptive replan in patients receiving ART. Survival outcomes and toxicity were compared between the ART and non-ART groups. Results: ART was implemented for 27 patients in whom adaptive replans significantly increased the median V98% of the clinical tumor volume from 96.5% to 98.1% and D98% from 60.5 to 62.7 Gy(RBE) compared with the as-scheduled plans (p < 0.001). The conformity and uniformity of the dose distribution improved (p < 0.001), with no significant differences in the doses to normal tissues (lungs, heart, esophagus, and spinal cord) from the as-scheduled plans (p > 0.05). The ART and non-ART groups demonstrated comparable local control, progression-free survival, and overall survival (p > 0.05). No grade 3 or higher radiation-related toxicities were observed. Conclusions: ART enhanced target dose coverage while maintaining acceptable normal tissue exposure, supporting weekly CT monitoring integration during CIRT for the timely intervention for anatomical variations, ensuring precise dose delivery in LA-NSCLC.


  • Open Access

    Ten-year outcomes of IMRT with chemotherapy versus IMRT alone for stage II–IVa nasopharyngeal carcinoma: a retrospective study

    by Xiao-Li Wang, Da-Qing Sun, Hui Yang, Yang Li, Xiu-Feng Li, Xiao-Long Chang, Xiang-Di Meng, Ya-Nan Zhang, Yun-Xiang Zhang, Fu-Rong Hao, et al.

    Background Concurrent chemoradiotherapy (CCRT) remains the cornerstone of treatment for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). However, data on long-term survival, particularly 10-year outcomes, are limited. Methods This retrospective study evaluated the clinical efficacy and acute hematologic toxicity of intensity-modulated radiation therapy (IMRT) in 177 newly diagnosed patients with locoregionally moderate or advanced NPC. Patients were categorized into three groups: IMRT alone; CCRT—including subgroups receiving neoadjuvant chemotherapy (NC) + CCRT, CCRT alone, and NC + CCRT + adjuvant chemotherapy (AC); and non-CCRT—including NC + IMRT + AC, and IMRT + AC. Results The median follow-up duration was 48.4 months (range, 3.0–178.9 months). Acute hematologic toxicities were generally mild, with 86.4% (153/177) of patients experiencing only grade 0–2 toxicity. The 10-year OS, PFS, LRFS, and DMFS rates were 66.6%, 75.3%, 91.9%, and 81.2%, respectively. OS differed significantly among the three treatment groups (P = 0.01). Both the CCRT and non-CCRT regimens were associated with improved 10-year OS compared to IMRT alone, with absolute increases of 29.4% and 26.1%, respectively (P = 0.01 for both comparisons). Conclusions In the era of IMRT, chemoradiotherapy was associated with manageable acute hematologic toxicity in patients with NPC. Distant metastasis, particularly in those with N3 disease, remained the predominant pattern of failure. Compared with IMRT alone, both CCRT (CCRT, NC + CCRT + AC, NC + CCRT) and non-CCRT (NC + IMRT + AC, IMRT + AC) demonstrated a potential survival benefit in newly diagnosed patients with locoregionally moderate or advanced NPC. These findings warrant further validation in prospective randomized clinical trials.


  • Open Access

    Preoperative lymph node metastasis risk assessment in invasive micropapillary carcinoma of the breast: development of a machine learning-based predictive model with a web-based calculator

    by Yan Zhang, Nan Wang, Yuxin Qiu, Yingxiao Jiang, Peiyan Qin, Xiaoxiao Wang, Yang Li, Xiangdi Meng, Furong Hao

    Invasive micropapillary carcinoma (IMPC) is a rare subtype of breast cancer characterized by a high risk of lymph node metastasis (LNM). The study aimed to identify predictors of LNM and to develop a machine learning (ML)-based risk prediction model for patients with breast IMPC. We retrospectively analyzed a cohort of 229 patients diagnosed with breast IMPC between 2019 and 2021. Patients were randomly assigned to training and test sets in a 7:3 ratio. Independent risk factors for LNM were identified using univariable and multivariable logistic regression analyses. Thirteen ML algorithms were trained and compared to determine the optimal model. Model performance was evaluated using the area under the curve (AUC), calibration plots, and decision curve analysis. Internal validation was performed using 100 iterations of tenfold cross-validation. LNM was present in 158 patients (69%). Tumor size, histological grade, progesterone receptor staining intensity, and lymphovascular invasion were identified as independent predictors of LNM (all p < 0.05). Among the 13 ML models, logistic regression (LR) demonstrated the best performance, achieving an AUC of 0.88 in the test set. A nomogram based on the LR model was constructed to facilitate clinical application, showing excellent calibration, clinical utility, and a classification accuracy of 76% (95% confidence interval: 70%–82%). The median AUC across cross-validation iterations was 0.83 (interquartile range: 0.76–0.91). This study identified key predictors of LNM in breast IMPC and developed a well-calibrated nomogram to support individualized treatment decision-making.


  • Open Access

    Survival benefits and toxicity effects of radiotherapy and immunotherapy treatments in melanoma patients with brain metastases: A meta-analysis

    by Jialing Wen, Xiangdi Meng, Wenchao Gu, Shenke Zhang, Li Sui, Gang Guo, Liang Yan, Wangcai Ren, Xuanzhang Tu, Kensuke Osada, et al.


  • Open Access

    Dynamic assessment of long-term survival in survivors with stage III non-small cell lung cancer: a novel conditional survival model with a web-based calculator

    by Xiangdi Meng, Peihe Wang, Jie Liu, Daqing Sun, Zhuojun Ju, Yuanyuan Cai

    Background: Conditional survival (CS) analysis can estimate further survival probabilities based on the time already survived, providing dynamic updates for prognostic information. This study aimed to develop a CS-nomogram to promote individualized disease management for stage III non-small cell lung cancer (NSCLC).Methods: This study included patients diagnosed with stage III NSCLC in the Surveillance, Epidemiology, and End Results database from 2010 to 2017 (N = 3,512). The CS was calculated as CS(y|x) = OS(y + x)/OS(x), where OS(y + x) and OS(x) were the overall survival (OS) in the year (y + x) and year x, respectively, calculated by the Kaplan–Meier method. We used the least absolute shrinkage and selection operator (LASSO) regression to identify predictors and developed the CS-nomogram based on these predictors and the CS formula.Results: The CS analysis provided real-time updates on survival, with 5-year OS improving dynamically from 14.4 to 29.9%, 47.9, 66.0, and 80.8% (after 1–4 years of survival). Six independent predictors (age, tumor size, N status, surgery, radiotherapy and chemotherapy) were identified for the development of the CS-nomogram and its web version (https://dynapp.shinyapps.io/NSCLC/). The model performed with an excellent concordance index (C-index) of 0.71 (95% CI: 0.70–0.72), and a median time-dependent AUC of 0.71–0.73 from 200 iterations 5-fold cross-validation.Conclusion: The study demonstrated the improvement in real-time OS over time in stage III NSCLC survivors and developed the novel CS-nomogram to provide patients with updated survival data. It provided novel insights into clinical decisions in follow-up and treatment for survivors, offering a convenient tool for optimize resource allocation.


  • Open Access

    Log odds of positive lymph nodes (LODDS)-based novel nomogram for survival estimation in patients with invasive micropapillary carcinoma of the breast

    by Xiangdi Meng, Furong Hao, Nan Wang, Peiyan Qin, Zhuojun Ju, Daqing Sun

    Background: Invasive micropapillary carcinoma (IMPC) of the breast is known for its high propensity for lymph node (LN) invasion. Inadequate LN dissection may compromise the precision of prognostic assessments. This study introduces a log odds of positive lymph nodes (LODDS) method to address this issue and develops a novel LODDS-based nomogram to provide accurate prognostic information. Methods: The study analyzed data from 1,901 patients with breast IMPC from the Surveillance, Epidemiology, and End Results database. It assessed the relationships between LODDS and the number of excised LN (eLN), positive LN (pLN), and the pLN ratio (pLNR), identifying an optimal threshold value using a restricted cubic spline method. Predictive factors were identified by the Cox least absolute shrinkage and selection operator (Cox-LASSO) regression and validated through multivariate Cox regression to construct a nomogram. The model's accuracy, discrimination, and utility were assessed. The study also explored the consequences of excluding LODDS from the nomogram and compared its effectiveness with the tumor-node-metastasis (TNM) staging system. Results: LODDS improved N status classification by identifying heterogeneity in patients with pLN ratios of 0% (pLN =0) or 100% (pLN =eLN) and setting -1.08 as the ideal cutoff. Five independent prognostic factors for breast cancer-specific survival (BCSS) were identified: tumor size, N status, LODDS, progesterone receptor status, and histological grade. The LODDS-based nomogram achieved a strong concordance index of 0.802 (95% CI: 0.741-0.863), surpassing both the version without LODDS and the conventional TNM staging in all tests. Conclusions: For breast IMPC, LODDS served as an independent prognostic factor, its effectiveness unaffected by the anatomical LN count, enhancing the accuracy of N staging. The LODDS-based nomogram showed promise in offering more personalized prognostic information.